Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes

Kaul, Subuhi; Gupta, Manasvi; Bandyopadhyay, Dhrubajyoti; Hajra, Adrija; Deedwania, Prakash; Roddy, Edward; Mamas, Mamas A.; Klein, Allan L.; Lavie, Carl J.; Fonarow, Gregg C.; Ghosh, Raktim

doi:10.1007/s40256-020-00459-1

Cited by 26 publications

(20 citation statements)

References 58 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A highly intriguing new observation is the potential role of colchicine, an old anti-inflammatory drug used for gout and pericarditis, in COVID-19. Recent RCTs in patients with coronary artery disease have shown significant reduction of CVD events with colchicine treatment [145]. A metaanalysis of eight studies included 5778 COVID-19 patients and 2668 patients who received colchicine treatment [146].…”

Section: Non-steroidal Anti-inflammatory Drugs (Nsaids) Including Colchicinementioning

confidence: 99%

Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications

et al. 2021

View full text Add to dashboard Cite

Purpose In the pathogenesis of severe COVID-19 complications, derangements of renin–angiotensin–aldosterone system (RAAS), vascular endothelial dysfunction leading to inflammation and coagulopathy, and arrhythmias play an important role. Therefore, it is worth considering the use of currently available drugs to protect COVID-19 patients with cardiovascular diseases. Methods We review the current experience of conventional cardiovascular drugs [angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers, anticoagulants, acetosalicylic acid, antiarrhythmic drugs, statins] as well as some other drug classes (antidiabetic drugs, vitamin D and NSAIDs) frequently used by older patients with cardiovascular diseases. Data were sought from clinical databases for COVID-19 and appropriate key words. Conclusions and recommendations are based on a consensus among all authors. Results Several cardiovascular drugs have a potential to protect patients with COVID-19, although evidence is largely based on retrospective, observational studies. Despite propensity score adjustments used in many analyses observational studies are not equivalent to randomised controlled trials (RCTs). Ongoing RCTs include treatment with antithrombotics, pulmonary vasodilators, RAAS-related drugs, and colchicine. RCTs in the acute phase of COVID-19 may not, however, recognise the benefits of long term anti-atherogenic therapies, such as statins. Conclusions Most current cardiovascular drugs can be safely continued during COVID-19. Some drug classes may even be protective. Age-specific data are scarce, though, and conditions which are common in older patients (frailty, comorbidities, polypharmacy) must be individually considered for each drug group.

show abstract

Section: Non-steroidal Anti-inflammatory Drugs (Nsaids) Including Colchicinementioning

confidence: 99%

Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In addition, there is a class of clusters focused on rheumatoid arthritis, which is not exploring the comorbid mechanisms of RA and CHD, but instead uses anti-inflammatory drugs to treat rheumatoid arthritis. Recent studies have focused on mechanistic intervention in cardiovascular disease with the anti-inflammatory drugs allopurinol ( 68 , 69 ) and colchicine ( 70 – 74 ), promising agents for intervention in cardiovascular disease ( 75 ). Moreover, there have been concentrated studies on gastrointestinal toxicity of NSAIDs ( 76 – 78 ), such as targeting gastrointestinal side effects of anti-inflammatory medications COX-2 inhibitors ( 79 , 80 ), focusing on the drug’s safety, and preventing adverse events ( 81 , 82 ).…”

Section: Discussionmentioning

confidence: 99%

Frontiers and hotspots evolution in anti-inflammatory studies for coronary heart disease: A bibliometric analysis of 1990–2022

Zhang

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundCoronary heart disease (CHD) is characterized by forming of arterial plaques composed mainly of lipids, calcium, and inflammatory cells. These plaques narrow the lumen of the coronary artery, leading to episodic or persistent angina. Atherosclerosis is not just a lipid deposition disease but an inflammatory process with a high-specificity cellular and molecular response. Anti-inflammatory treatment for CHD is a promising therapy; several recent clinical studies (CANTOS, COCOLT, and LoDoCo2) provide therapeutic directions. However, bibliometric analysis data on anti-inflammatory conditions in CHD are lacking. This study aims to provide a comprehensive visual perspective on the anti-inflammatory research in CHD and will contribute to further research.Materials and methodsAll the data were collected from the Web of Science Core Collection (WoSCC) database. We used the Web of Science’s systematic tool to analyze the year of countries/regions, organizations, publications, authors, and citations. CiteSpace and VOSviewer were used to construct visual bibliometric networks to reveal the current status and emerging hotspot trends for anti-inflammatory intervention in CHD.Results5,818 papers published from 1990 to 2022 were included. The number of publications has been on the rise since 2003. Libby Peter is the most prolific author in the field. “Circulation” was ranked first in the number of journals. The United States has contributed the most to the number of publications. The Harvard University System is the most published organization. The top 5 clusters of keywords co-occurrence are inflammation, C-reactive protein, coronary heart disease, nonsteroidal anti-inflammatory, and myocardial infarction. The top 5 literature citation topics are chronic inflammatory diseases, cardiovascular risk; systematic review, statin therapy; high-density lipoprotein. In the past 2 years, the strongest keyword reference burst is “Nlrp3 inflammasome,” and the strongest citation burst is “Ridker PM, 2017 (95.12).”ConclusionThis study analyzes the research hotspots, frontiers, and development trends of anti-inflammatory applications in CHD, which is of great significance for future studies.

show abstract

“…Cardiovascular disease is a leading cause of mortality in the United States, which stresses the importance of identifying risk factors and working on prevention [18]. Numerous studies have reported gout as an independent risk factor for MI and colchicine significantly lowering the risk of ischemic cardiovascular disease [4,19]. CPPD is a newly emerging risk factor for adverse cardiovascular events, and additional large-scale studies are warranted to explore this relationship further.…”

Section: Discussionmentioning

confidence: 99%

Synovium to Myocardium: A Case of Calcium Pyrophosphate Dihydrate Crystal Arthritis Associated With Myocardial Infarction

Raza¹,

Rana²,

Arif³

et al. 2023

Cureus

View full text Add to dashboard Cite

Both gout and pseudogout are crystal-induced arthropathies. Here, we report a case of acute calcium pyrophosphate dihydrate (CPPD) arthritis associated with type 1 myocardial infarction (MI). An 83-year-old female presented to our emergency department with generalized weakness and bilateral lower extremity edema. Her left foot was noted to be more inflamed compared to the right, with cardinal signs of pain, swelling, erythema, and warmth. A presumptive diagnosis of cellulitis was made, and antibiotics were initiated. Further investigations revealed elevated troponins with new-onset bundle branch block, ST, and Twave changes on electrocardiogram, indicating a type 1 MI. After a review of the patient's history, imaging of the extremity, elevated inflammatory markers, and the typical distribution and pattern of inflammation, the diagnosis was changed to pseudogout. Steroids and colchicine were initiated, providing instant relief. This case highlights a possible association between cardiovascular disease and pseudogout, emphasizing the need for further studies regarding this relationship. Despite being rare, physicians should be made aware of this relationship, especially in patients with a history of CPPD arthritis presenting with type 1 MI.

show abstract

Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes

Cited by 26 publications

References 58 publications

Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications

Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications

Frontiers and hotspots evolution in anti-inflammatory studies for coronary heart disease: A bibliometric analysis of 1990–2022

Synovium to Myocardium: A Case of Calcium Pyrophosphate Dihydrate Crystal Arthritis Associated With Myocardial Infarction

Contact Info

Product

Resources

About